The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28650658 |
54 |
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. |
Shandong University |
28337327 |
18 |
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach. |
Novartis Institutes For Biomedical Research |
25406853 |
72 |
Selective inhibitors of protein methyltransferases. |
Icahn School Of Medicine At Mount Sinai |
25032507 |
43 |
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. |
University Of North Carolina At Chapel Hill |
23879463 |
36 |
A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. |
Baylor College Of Medicine |
23433670 |
15 |
Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. |
Entremed |
24900432 |
51 |
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. |
TBA |
22924785 |
85 |
Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. |
Baylor College Of Medicine |
22975593 |
62 |
Oncoepigenomics: making histone lysine methylation count. |
TBA |
18189347 |
12 |
Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase. |
Toronto General Research Institute |
17439112 |
46 |
Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. |
Ligand Pharmaceuticals |